Figure S4 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

• MAIN FINDING: The humanized CD36-blocking antibody effectively enhances antitumor immunity against liver cancer.
• KEY EVIDENCE: The MYCOE/CTNNB1N90 mouse model demonstrated significant immune response upon treatment with CD36 antibody.
• APPROACH: The study characterized liver cancer progression in a lipid-rich environment using a specific mouse model.
• SIGNIFICANCE: This research highlights a potential new strategy to improve treatment outcomes for liver cancer patients.